Von Willebrand factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 3, 2014, Pages 331-338

  Maieron, A ^a,b   Salzl, P ^b   Peck Radosavljevic, M ^b   Trauner, M ^b   Hametner, S ^a   Schofl R ^a   Ferenci, P ^b   Ferlitsch, M ^b  

^a Linz General Hospital   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR;

ADULT; APRI SCORE; AREA UNDER THE CURVE; ARTICLE; CHILD PUGH SCORE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DISEASE MARKER; FCI SCORE; FEMALE; FI SCORE; FIB 4 SCORE; FORNS SCORE; HEPATITIS C; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; VITRO SCORE;

ADULT; BIOLOGICAL MARKERS; BIOPSY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; VON WILLEBRAND FACTOR;

EID: 84891848248     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12564     Document Type: Article

References (44)

1. Lavanchy D,. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl. 1): 74-81.
2. Shepard CW, Finelli L, Alter MJ,. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
3. Afdhal NH,. The natural history of hepatitis C. Semin Liver Dis 2004; 24 (Suppl. 2): 3-8.
4. Thompson Coon J, Rogers G, Hewson P, et al,. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 2008; 98: 1166-75.
5. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
6. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
7. European Association of the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 2012; 32 (Suppl. 1): 2-8.
8. Hezode C, Fontaine H, Dorival C, et al,. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59: 434-41.
9. Sebastiani G, Alberti A,. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12: 3682-94.
10. West J, Card TR,. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology 2010; 139: 1230-7.
11. Terjung B, Lemnitzer I, Dumoulin FL, et al,. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003; 67: 138-45.
12. Beinhardt S, Staettermayer AF, Rutter K, et al,. Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias? Hepatology 2012; 55: 30-8.
13. Castera L,. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142: 1293-302. e4.
14. Ahmad W, Ijaz B, Javed FT, et al,. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol 2011; 11: 44.
15. Ohta T, Sakaguchi K, Fujiwara A, et al,. Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama 2006; 60: 77-84.
16. Hubbard AR, Heath AB,. Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02/150). J Thromb Haemost 2004; 2: 1380-4.
17. Ferlitsch M, Reiberger T, Hoke M, et al,. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 2012; 56: 1439-47.
18. Iannacone M, Sitia G, Isogawa M, et al,. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med 2005; 11: 1167-9.
19. Ferro D, Quintarelli C, Lattuada A, et al,. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996; 23: 1377-83.
20. van Mourik JA, Boertjes R, Huisveld IA, et al,. von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999; 94: 179-85.
21. Iwakiri Y, Groszmann RJ,. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007; 46: 927-34.
22. Matei V, Rodriguez-Vilarrupla A, Deulofeu R, et al,. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology 2006; 44: 44-52.
23. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G,. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-47.
24. La Mura V, Reverter JC, Flores-Arroyo A, et al,. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut 2011; 60: 1133-8.
25. La Mura V, Reverter JC, Flores-Arroyo A, et al,. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut 2010; 60: 1133-8.
26. Hezode C, Zoulim F, Poynard T,; ANRS CO20 CUPIC study group. Safety of Telaprevir or Boceprevir in combination with Peginterferon alpha/Ribavirin, in cirrhotic non responders. Results of the french early access program (ANRS CO20-CUPIC). J Hepatol 2013; 59: 434-41.
27. Lisman T, Bongers TN, Adelmeijer J, et al,. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.
28. Pramhas S, Homoncik M, Ferenci P, et al,. von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4. Antivir Ther 2010; 15: 831-9.
29. Ferenci P, Laferl H, Scherzer TM, et al,. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology 2010; 138: 503-12, 512.e1.
30. Formann E, Steindl-Munda P, Hofer H, et al,. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 2006; 23: 507-11.
31. Cadranel JF, Rufat P, Degos F,. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81.
32. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
33. Homoncik M, Ferlitsch A, Ferenci P, et al,. Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. Aliment Pharmacol Ther 2005; 21: 49-55.
34. Attallah AM, Omran MM, Farid K, et al,. Development of a novel score for liver fibrosis staging and comparison with eight simple laboratory scores in large numbers of HCV-monoinfected patients. Clin Chim Acta 2012; 413: 1725-30.
35. Baranova A, Lal P, Birerdinc A, Younossi ZM,. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol 2011; 11: 91.
36. Forns X, Ampurdanes S, Llovet JM, et al,. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
37. Myers RP, Elkashab M, Ma M, Crotty P, Pomier-Layrargues G,. Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. Can J Gastroenterol 2010; 24: 661-70.
38. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K,. The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33: 196-200.
39. Bedossa P, Dargere D, Paradis V,. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
40. Ziol M, Handra-Luca A, Kettaneh A, et al,. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
41. Gara N, Zhao X, Kleiner DE, Liang TJ, Hoofnagle JH, Ghany MG,. Discordance Among Transient Elastography, Aminotransferase to Platelet Ratio Index, and Histologic Assessments of Liver Fibrosis in Patients with Chronic Hepatitis C. Clin Gastroenterol Hepatol 2013; 11: 303-8.e1.
42. Martinez SM, Fernandez-Varo G, Gonzalez P, et al,. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 138-48.
43. Vallet-Pichard A, Mallet V, Nalpas B, et al,. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6.
44. Wai CT, Greenson JK, Fontana RJ, et al,. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.